Literature DB >> 8711757

Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.

M Adler1, D A Macdonald, L C Sellin, G W Parker.   

Abstract

The actions of the K+ channel blocker, 3,4-diaminopyridine (3,4-DAP), were studied in the rat extensor digitorum longus (EDL) muscle following local inhibition of neuromuscular transmission by botulinum neurotoxin (BoNT). Local paralysis of the EDL muscle was induced by s.c. injections of BoNT serotypes A, B, E or F over the anterior tibialis muscle. One to 14 days later, the rats were anesthetized with urethane, and isometric twitch tensions following stimulation of the peroneal nerve were measured in situ. Muscles were paralyzed within 24 hr of administration of 5 mouse LD50 units (U) of BoNT/A and remained inhibited for the entire 14-day period of observation. Similar levels of inhibition, but of shorter duration, were observed after local injection of 20 U of BoNT/E, 10(4) U of BoNT/B or 20 U of BoNT/F. 3,4-DAP (4 mg/kg, i.v.) potentiated twitch tensions markedly in BoNT/A intoxicated muscle. The increase in tension developed rapidly (halftime = 5.81 +/- 0.6 min), persisted for approximately 1 hr, then decayed slowly with a halftime of 25.2 +/- 4.6 min. Subsequent administration of 3,4-DAP restored tensions to the original maxima, and this procedure could be repeated up to eight times with no decrement. The action of 3,4-DAP was comparable when given 1, 2, 3 or 7 days after BoNT/A and enhanced when administered 14 days after toxin injection. 3,4-DAP was less effective in reversing BoNT/E-induced muscle paralysis and nearly ineffective in antagonizing the paralytic actions of BoNT/B or BoNT/F. The results indicate that 3,4-DAP is of benefit in BoNT/A and BoNT/E intoxication, but is of marginal value after exposure to serotypes B and F.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8711757     DOI: 10.1016/0041-0101(95)00127-1

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  8 in total

Review 1.  SNARE requirements en route to exocytosis: from many to few.

Authors:  Ralf Mohrmann; Jakob B Sørensen
Journal:  J Mol Neurosci       Date:  2012-03-17       Impact factor: 3.444

2.  An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection.

Authors:  Temeri D Wilder-Kofie; Carolina Lúquez; Michael Adler; Janet K Dykes; JoAnn D Coleman; Susan E Maslanka
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

3.  Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Carmen C Garcia; Kormakur Hognason; Katerina Capková; Scott T Moe; Alan R Jacobson; Kim D Janda; Joseph J McArdle
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

4.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

5.  Persistence of Botulinum neurotoxin inactivation of nerve function.

Authors:  Charles B Shoemaker; George A Oyler
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

6.  Symptomatic treatment of botulism with a clinically approved small molecule.

Authors:  Edwin Vazquez-Cintron; James Machamer; Celinia Ondeck; Kathleen Pagarigan; Brittany Winner; Paige Bodner; Kyle Kelly; M Ross Pennington; Patrick McNutt
Journal:  JCI Insight       Date:  2020-01-30

7.  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Authors:  Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2011-09-14       Impact factor: 3.641

8.  A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.

Authors:  Tyler L Harris; Colin A Lowery; Mark S Hixon; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2014-07-11       Impact factor: 4.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.